New CFS clinical study offered by Dr. Jon Kaiser in San Francisco Bay Area

[Guest guest]

Hi, all.

I want to tell you about a new treatment study for chronic fatigue syndrome that

is available to patients in the San Francisco Bay Area, or to those able to

travel to this area. It was announced today.

The study is being conducted by Dr. Jon D. Kaiser, M.D., who practices in Mill

Valley, CA, and who is the CEO and Medical Director of K-PAX Pharmaceuticals,

Inc. Dr. Kaiser has extensive past experience in the treatment of HIV/AIDS, and

is currently specializing in chronic fatigue syndrome.

In order to participate in this study, patients will need to be able to visit

Dr. Kaiser's office once. His office is located 30 minutes north of San

Francisco. In the office visit, a patient will be screened to determine whether

she/he satisfies the criteria for the diagnosis of chronic fatigue syndrome.

Conditions that may exclude a person from this trial are significant

fibromyalgia, a history of heart disease, uncontrolled high blood pressure,

major depression, or ulcer disease.

The treatment will last for one month. It will consist of " a low dosage of a

currently available medication with a potent nutrient-antioxidant cocktail that

boosts immune function to provide CFS patients with a healthy and balanced

increase in their energy level. " Specifically, the treatment will consist of

the commercially available K-PAX Immune Support Formula (see www.kpaxpharm.com)

combined with a low dosage of Ritalin.

According to Dr. Kaiser, the rationale for this combination is " By

pharmacologically boosting central nervous system signaling from the brain, plus

concurrently enhancing mitochondrial energy production with potent

micronutrients, it is possible to initiate a reintegration of the

neuro-endocrine-immune axis, providing CFS patients with an improved quality of

life and the potential for complete cure. "

The office visit and the nutritional supplement for the study will be provided

free of charge. This will be an open-label clinical study with no placebo

group, so everyone who is selected to participate will receive the actual

treatment.

Dr. Kaiser reports that this treatment " has already shown promise in a

significant number of CFS patients. "

There will be an opportunity to continue this treatment beyond one month if a

patient experiences benefit and desires to continue.

(I am not financially associated with Dr. Kaiser or with K-PAX Pharmaceuticals,

Inc.) For more information or to enroll in the trial, please email Anne

Lahaderne at a.lahaderne@... or call her at (415) 381-7655.

Best regards,

Rich